Skip to Content

Rydex Biotechnology Inv RYOIX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 69.49  /  −1.35 %
  • Total Assets 102.6 Mil
  • Adj. Expense Ratio
    1.390%
  • Expense Ratio 1.390%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield
  • Turnover 61%

USD | NAV as of Apr 16, 2024 | 1-Day Return as of Apr 16, 2024, 12:24 AM GMT+0

Morningstar’s Analysis RYOIX

Will RYOIX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of an Average People Pillar rating and a Below Average Process Pillar rating limit Rydex Biotechnology Inv to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYOIX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 40.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

9.09 10.3 Mil
Healthcare

Amgen Inc

5.75 6.5 Mil
Healthcare

Regeneron Pharmaceuticals Inc

4.49 5.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.20 4.8 Mil
Healthcare

Gilead Sciences Inc

3.66 4.1 Mil
Healthcare

Corteva Inc

3.17 3.6 Mil
Basic Materials

Moderna Inc

2.87 3.2 Mil
Healthcare

AstraZeneca PLC ADR

2.56 2.9 Mil
Healthcare

Biogen Inc

2.53 2.9 Mil
Healthcare

Illumina Inc

2.41 2.7 Mil
Healthcare